Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-α receptors in a human colon adenocarcinoma (Colo 205) cell line

Cancer Research

Volumn 58, Issue 17, 1998, Pages 4001-4007

  Lombard, Mark A ^a   Wallace, Tanya L ^a   Kubicek, Marc F ^a   Petzold, Gary L ^a   Mitchell, Mark A ^a   Hendges, Susan K ^a   Wilks, John W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; CGS 27023A; CT 1418; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; COLLAGEN DEGRADATION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; METASTASIS; NEUROMODULATION; PRIORITY JOURNAL; RECEPTOR SOLUBILIZATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; BINDING SITES; COLONIC NEOPLASMS; HUMANS; METALLOENDOPEPTIDASES; PROTEASE INHIBITORS; RECEPTORS, TUMOR NECROSIS FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR CELLS, CULTURED;

EID: 0032170034     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Coussens, L. M., and Werb, Z. Matrix metalloproteinases and the development of cancer. Chem. Biol., 3: 895-904, 1996.
2. MacDougall, J. R., and Matrisian, L. M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion, and metastasis. Cancer Metastasis Rev., 14: 351-362, 1995.
3. Stetler-Stevenson, W. G., Hewitt, R., and Corcoran, M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol., 7: 147-154, 1996.
4. Brown, P. D., and Giavazzi, R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol., 6: 967-974, 1995.
5. Beckett, R. P., Davidson, A. H., Drummond, A. H., Huxley, P., and Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today, 1: 16-26, 1996.
6. Wang, X., Fu, X., Brown, P. D., Crimmin, M. J., and Hoffman, R. M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res., 54: 4726-4728, 1994.
7. Watson, S. A., Morris, T. M., Parsons, S. L., Steele, R. J. C., and Brown, P. D. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br. J. Cancer, 74: 1354-1358, 1996.
8. Wojtowicz-Praga, S., Low, J., Marshall, J., Ness, E., Dickson, R., Barter, J., Sale, M., McCann, P., Moore, J., Cole, A., and Hawkins, M. J. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest. New Drugs, 14: 193-202, 1996.
9. Wojtowicz-Praga, S. N., Dickson, R. B., and Hawkins, M. J. Matrix metalloproteinase inhibitors. Invest. New Drugs, 15: 61-75, 1997.
10. Denis, L. J., and Verweij, J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs, 15: 175-185, 1997.
11. Rasmussen, H. S., and McCann, P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther., 75: 69-75, 1997.
12. Hooper, N. M., Karran, E. H., and Turner, A. J. Membrane protein secretases. Biochem. J., 321: 265-279, 1997.
13. Crowe, P. D., Walter, B. N., Mohler, K. M., Otten-Evans, C., Black, R. A., and Ware, C. F. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J. Exp. Med., 181: 1205-1210, 1995.
14. Mullberg, J., Durie, F. H., Otten-Evans, C., Alderson, M. R., Rose-John, S., Cosman, D., Black, R. A., and Mohler, K. M. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol., 155: 5198-5205, 1995.
15. Williams, L. M., Gibbons, D. L., Gearing, A., Maini, R. N., Feldmann, M., and Brennan, F. M. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 receptor shedding and TNFα processing in RA synovial membrane cell cultures. J. Clin. Invest., 12: 2833-2841, 1996.
16. Darnay, B. G., and Aggarwal, B. B. Early events in TNF signaling: a story of associations and dissociations. J. Leukocyte Biol., 61: 559-566, 1997.
17. Yuan, J. Transducing signals of life and death. Curr. Opin. Cell Biol., 9: 247-251, 1997.
18. Loetscher, H., Pan, Y-C. E., Lahm, H-W., Gentz, R., Brockhaus, M., Tabuchi, H., and Lesslauer, W. Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor. Cell, 61: 351-359, 1990.
19. Schall, T. J., Lewis, M., Koller, K. J., Lee, A., Rice, G. C., Wong, G. H. W., Gatanaga, T., Granger, G. A., Lentz, R., Raab, H., Kohr, W. J., and Goeddel, D. V. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell, 61: 361-370, 1990.
20. Heller, R. A., Song, K., Onasch, M. A., Fischer, W. H., Chang, D., and Ringold, G. M. Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor. Proc. Natl. Acad. Sci. USA, 87: 6151-6155, 1990.
21. Kohno, T., Brewer, M. T., Baker, S. L., Schwartz, P. E., King, M. W., Hale, K. K., Squires, C. H., Thompson, R. C., and Vannice, J. L. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc. Natl. Acad. Sci. USA, 87: 8331-8335, 1990.
22. Porteu, F., and Nathan, C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med., 172: 599-607, 1990.
23. Philippe, C., Roux-Lombard, P., Fouqueray, B., Perez, J., Dayer, J-M., and Baud, L. Membrane expression and shedding of tumor necrosis factor receptors during activation of human blood monocytes: regulation by desferrioxamine. Immunology, 80: 300-305, 1993.
24. Leeuwenberg, J. F. M., Jeunhomme, T. M. A. A., and Buurman, W. A. Slow release of soluble TNF receptors by monocytes in vitro. J. Immunol., 152: 4036-4043, 1994.
25. Martinet, N., Charles, T., Vaillant, P., Vignaud, J-M., Lambert, J., and Martinet, Y. Characterization of a tumor necrosis factor-I inhibitor activity in cancer patients. Am. J. Respir. Cell Mol. Biol., 6: 510-515, 1992.
26. Gruss, H-J., Duyster, J., and Herrmann, F. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Ann. Oncol., 7 (Suppl. 4): S19-S26, 1996.
27. Grosen, E. A., Granger, G. A., Gatanaga, M., Ininns, E. K., Hwang, C., DiSaia, P., Berman, M., Manetta, A., Emma, D., and Gatanaga, T. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy. Gynecol. Oncol., 50: 68-77, 1993.
28. Black, P. H. Shedding from normal and cancer-cell surfaces. N. Engl. J. Med., 303: 1415-1416, 1980.
29. Langkopf, F., and Atzpodien, J. Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet, 344: 57-58, 1994.
30. Bergmann, U., Tuuttila, A., Stetler-Stevenson, W. G., and Tryggvason, K. Autolytic activation of recombinant human 72 kilodalton type IV collagenase. Biochemistry, 34: 2819-2825, 1995.
31. Stack, M. S., and Gray, R. D. Comparison of vertebrate collagenase and gelatinase using a new fluorogenic substrate peptide. J. Biol. Chem., 264: 4277-4281, 1989.
32. Weisner, R., and Troll, W. A new assay for proteases using fluorescent labelling of proteins. Anal. Biochem., 121: 290-294, 1982.
33. Galve-de Rochemonteix, B., Nicod, L. P., and Dayer, J-M. Tumor necrosis factor soluble receptor 75: the principal receptor form released by human alveolar macrophages and monocytes in the presence of interferon K. Am. J. Respir. Cell Mol. Biol., 14: 279-287, 1996.
34. Gallea-Robache, S., Morand, V., Millet, S., Bruneau, J-M., Bhatnagar, N., Chouaib, S., and Roman-Roman, S. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine, 9: 340-346, 1997.
35. Smith, M. R., Kung, H., Durum, S. K., Colburn, N. H., and Sun, Y. TIMP-3 induces cell death by stabilizing TNF-α receptors on the surface of human colon carcinoma cells. Cytokine, 9: 770-780, 1997.
36. Hayakawa, T., Yamashita, K., Ohuchi, E., and Shinagawa, A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci., 107: 2373-2379, 1994.
37. Stocker, W., Grams, F., Baumann, U., Reinemer, P., Gomis-Ruth, F-X., McKay, D. B., and Bode, W. The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci., 4: 823-840, 1995.
38. Maskos, K., Fernandez-Catalan, C., Huber, R., Bourenkov, G. P., Bartunik, H., Ellestad, G. A., Pranitha, R., Wolfson, M. F., Rauch, C. T., Castner, B. J., Davis, R., Clarke, H. R. G., Petersen, M., Fitzner, J. N., Cerretti, D. P., March, C. J., Paxton, R. J., Black, R. A., and Bode, W. Crystal structure of the catalytic domain of human tumor necrosis factor-I-converting enzyme. Proc. Natl. Acad. Sci. USA, 95: 3408-3412, 1998.
39. Gearing, A. J. H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M., and Woolley, K. Processing of tumour necrosis factor-I precursor by metalloproteinases. Nature (Lond.), 370: 555-557, 1994.
40. Mohler, K. M., Sleath, P. R., Fitzner, J. N., Cerretti, D. P., Alderson, M., Kerwar, S. S., Torrance, D. S., Otten-Evans, C., Greenstreet, T., Weerawarna, K., Kronheim, S. R., Petersen, M., Gerhart, M., Kozlosky, C. J., March, C. J., and Black, R. A. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (Lond.), 370: 218-220, 1994.
41. McGeehan, G. M., Becherer, J. D., Bast, R. C., Jr., Boyer, C. M., Champion, B., Connolly, K. M., Conway, J. G., Furdon, P., Karp, S., Kidao, S., McElroy, A. B., Nichols, J., Pryzwansky, K. M., Schoenen, F., Sekut, L., Truesdale, A., Verghese, M., Warner, J., and Ways, J. P. Regulation of tumour necrosis factor-I processing by a metalloproteinase inhibitor. Nature (Lond.), 370: 558-561, 1994.
42. Millar, A. W., Brown, P. D., Moore, J., Galloway, W. A., Cornish, A. G., Lenehan, T. J., and Lynch, K. P. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol., 45: 21-26, 1998.
43. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
44. Moss, M. L., Jin, S-L. C., Milla, M. E., Bickett, D. M., Burkhart, W., Carter, H. L., Chen, W-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., Kost, T. A., Lambert, M. H., Leesnitzer, M. A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L. K., Schoenen, F., Seaton, T., Su, J-L., Warner, J., Willard, D., and Becherer, J. D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-I. Nature (Lond.), 385: 733-736, 1997.
45. Kriegler, M., Perez, C., DeFay, K., Albert, I., and Lu, S. D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell, 53: 45-53, 1988.
46. Perez, C., Albert, I., DeFay, K., Zachariades, N., Gooding, L., and Kriegler, M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell, 63: 251-258, 1990.
47. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., and Scheurich, P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell, 83: 793-802, 1995.